Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.
It is valuable for pharmacists to understand exactly how price transparency data are sourced, what information can be found, antitrust concerns, and implications for the pharmaceutical industry.
For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.